GSK’s disinvestment of Chiron Behring to Bharat Biotech

Bharat Biotech’s recent plans to acquire Chiron Behring Vaccine Private Limited from GlaxoSmithKline Asia, is expected to boost the company’s rabies vaccine manufacturing capacity from the current 10 million doses to 15 million doses. With Bharat Biotech announcing its decision to acquire Chiron Behring from GlaxoSmithKline Asia, the leading Indian vaccine maker will now have 100 per cent equity stake in Chiron Behring Vaccines, which is located at Ankleshwar in Gujarat.

Chiron Behring Vaccines was formed as a result of the purchase of the vaccines business of Hoechst AG by Chiron Corporation USA. It is one of the largest manufacturers of high quality rabies vaccines in the world.

Chiron Behring Vaccines is a WHO pre-qualified manufacturer of rabies vaccines, eligible for supplies to UN agencies and has product registrations in more than 20 countries. The rabies vaccine manufactured at Ankleshwar is a result of decades of research and product development.

What this deal mean to Bharat Biotech?

• While on the other hand Bharat Biotech has a wide portfolio of vaccines, with market access to more than 70 countries.
• The addition of this rabies vaccine will establish Bharat Biotech as a global leader in rabies vaccines manufacturing.
• Bharat Biotech plans to enhance upon the manufacturing capabilities at Chiron Behring Vaccines and expand market access through product registrations in additional high demand countries.